Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that post-finasteride syndrome and post-SSRI sexual dysfunction share potential etiopathogenetic mechanisms involving brain modulators, neurotransmitters, and gut microbiota, although more research is needed to understand these conditions fully.

This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.

This article highlights the lack of attention to the impact of polycystic ovarian syndrome on women's identity, mental health, and quality of life in India without offering new findings.

This case-control study in Missan Province, Iraq, found that married women with PCOS had higher rates of obesity and menstrual irregularities, along with elevated testosterone, LH, and insulin levels, compared to healthy controls, highlighting significant hormonal and metabolic complications.

This meta-analysis found that women with polycystic ovary syndrome have over a 2.5-fold higher risk of depression compared to healthy women.

PFS affects some women, steroids easily bought online, hypogonadism info unreliable, low testosterone linked to CVD.

In this study, the authors reported that depression and anxiety are more prevalent in patients with polycystic ovary syndrome compared to healthy women, reinforcing the need for routine mental health screening in this population.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

In this study, dermatologists from the Spanish Hair and Nail Disorders Group viewed post-finasteride syndrome as rare and primarily of psychiatric origin, with limited scientific evidence supporting its existence.

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

Among women with polycystic ovary syndrome, this study observed a median depression incidence of 36.6%, significantly higher than the 14.2% reported in women without the syndrome.

This review discusses the occurrence of persistent sexual, physical, neurological, and psychiatric side effects known as post-finasteride syndrome after 5x-reductase inhibitor treatment, and emphasizes the importance of evaluating these risks for patients with benign prostatic hyperplasia or androgenic alopecia.

This study found that women with PCOS exhibited higher levels of alexithymia and body uneasiness compared to healthy controls, affecting their psychological and social well-being.

This review discusses the renaming of Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome, reflecting its broader recognition as a multisystem metabolic-endocrine disorder, and reports no new clinical results.

This study found that women with PCOS and amenorrhea have a higher prevalence of insulin resistance, prediabetes, and dyslipidemia compared to those with oligomenorrhea or eumenorrhea, suggesting that menstrual dysfunction severity could be an indicator of heightened cardiometabolic risk in these women.

This study found that cyclic MPA is as effective as OCPs in resuming ovulation among women with PCOS, offering a viable alternative for those who cannot or choose not to use OCPs.

Women with pituitary adenomas often have reproductive issues, like irregular periods and trouble getting pregnant, but not always breast milk production without pregnancy.

In this study, depression and anxiety were prevalent in Thai women with PCOS, with hirsutism being a key factor linked to these mental health issues, suggesting a need for targeted screening.

This study found that women with polycystic ovary syndrome have significantly higher scores for affective temperaments and anxiety and depression than healthy controls, suggesting risk for depressive and anxiety disorders.

Patients with Polycystic Ovary Syndrome in this study had significantly higher anxiety and depression scores compared to controls, but showed no significant differences in temperament and character traits.

This study in Urmia, Iran, characterized women with PCOS, POF, and EMs, revealing a PCOS prevalence of 17.69% and emphasizing significant lifestyle and health differences compared to healthy individuals, particularly in rural areas, alongside identifying key screening features for POF and EMs.

This study found that medroxyprogesterone acetate treatment in women with PCOS reduced hyperandrogenism-related hormonal levels and improved skin conditions without affecting lipid or carbohydrate metabolism.

This study found that women with polycystic ovary syndrome reported significantly higher levels of psychological symptoms, such as depression and anxiety, compared to healthy controls, with higher stress and lower self-efficacy linked to increased symptom severity.

This review discusses polycystic ovarian syndrome, highlighting its symptoms, potential causes, and treatment options, but reports no new clinical results.

In this study using a PCOS mouse model with added stress, researchers observed that combining corticosterone with dihydrotestosterone partially supported the hypothesis of behavioral changes, aligning with depression and anxiety-linked symptoms in women with PCOS.

This study reported that women with Polycystic Ovary Syndrome have higher rates of clinically significant insomnia and excessive daytime sleepiness than women without the condition, highlighting the need for sleep disorder screening in this population.

This study found that six months of combined estrogen-progestin pill therapy led to a significant reduction in serum AMH levels and improvement in hyperandrogenic symptoms among women with PCOS.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.

This systematic review found that probiotic supplementation improved sleep quality, reduced depressive symptoms, and enhanced aspects of quality of life in women with PCOS, though the findings are limited by a small number of studies and variable methods.

This review discusses AMH and ovarian morphology as complementary markers in diagnosing PCOS/PMOS and reports no new clinical results, highlighting the need for a multidomain approach in diagnosis and treatment.